2023

Six months have elapsed since the Precision Immunotherapy Alliance (PRIMA) commenced its operations and Director Kalle Malmberg reflects on the past months events.

Feature story in Aftenposten Dec 7, 2023, by PRIMA Co-Director Johanna Olweus, Kjetil Taskén and John Arne Røttingen on the use of mRNA in cancer treatment and in the prevention of infections.

PRIMA was so lucky to host a group of highly motivated and interested students from Sandvika VGS who used a day in the center to learn more about precision immunotherapy.

A recent publication from the Olweus group entitled "A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo" is profiled in ACIR. 

Mage Biologics Inc (Mage Bio) is a new U.S.-based biotech company developing a tailored antibody that can be administered orally for treatment of chronic diseases in the gut.

The Laboratory of Adaptive Immunity and Homeostasis, headed by PRIMA PI Jan Terje Andersen, has signed a framework agreement with Roche Diagnostics GmbH and entered a research collaboration with the aim to gain a deeper understanding on how FcRn-targeted molecules are handled in both in vitro and in vivo systems.

The whole PRIMA family was gathered for the first scientific meeting in the centre from August 30-31 with the aim of getting to know each other’s expertise and research.

Congratulations to our brilliant postdoc Zsofia Fôldvari on her paper in the Nature Partner Journal (NPJ) Vaccines, outlining a much-needed strategy to select safe T-cell receptors!